Abstract:Protein aggregation is common to dozens of diseases including prionoses, diabetes, Parkinson’s and Alzheimer’s. Over the past 15 years, there has been a paradigm shift in understanding the structural basis for these proteinopathies. Precedent for this shift has come from investigation of soluble Aβ oligomers (AβOs), toxins now widely regarded as instigating neuron damage leading to Alzheimer’s dementia. Toxic AβOs accumulate in AD brain and constitute long-lived alternatives to the disease-defining Aβ fibrils deposited in amyloid plaques. Key experiments using fibril-free AβO solutions demonstrated that while Aβ is essential for memory loss, the fibrillar Aβ in amyloid deposits is not the agent. The AD-like cellular pathologies induced by AβOs suggest their impact provides a unifying mechanism for AD pathogenesis, explaining why early stage disease is specific for memory and accounting for major facets of AD neuropathology. Alternative ideas for triggering mechanisms are being actively investigated. Some research favors insertion of AβOs into membrane, while other evidence supports ligand-like accumulation at particular synapses. Over a dozen candidate toxin receptors have been proposed. AβO binding triggers a redistribution of critical synaptic proteins and induces hyperactivity in metabotropic and ionotropic glutamate receptors. This leads to Ca2+ overload and instigates major facets of AD neuropathology, including tau hyperphosphorylation, insulin resistance, oxidative stress, and synapse loss. Because different species of AβOs have been identified, a remaining question is which oligomer is the major pathogenic culprit. The possibility has been raised that more than one species plays a role. Despite some key unknowns, the clinical relevance of AβOs has been established, and new studies are beginning to point to co-morbidities such as diabetes and hypercholesterolemia as etiological factors. Because pathogenic AβOs appear early in the disease, they offer appealing targets for therapeutics and diagnostics. Promising therapeutic strategies include use of CNS insulin signaling enhancers to protect against the presence of toxins and elimination of the toxins through use of highly specific AβO antibodies. An AD-dependent accumulation of AβOs in CSF suggests their potential use as biomarkers and new AβO probes are opening the door to brain imaging. Overall, current evidence indicates that Aβ oligomers provide a substantive molecular basis for the cause, treatment and diagnosis of Alzheimer’s disease.

Reactive oxygen species may cause amyloid beta aggregation by free radical polymerization

Role of oxidative stress in Alzheimer's disease.

A Comprehensive Study on the Generation of Reactive Oxygen Species in Cu-Aβ-catalyzed Redox Processes.

The Interplay of Protein Aggregation, Genetics, and Oxidative Stress in Alzheimer's Disease: Role for Natural Antioxidants and Immunotherapeutics

Energy Landscapes of the Monomer and Dimer of the Alzheimer’s Peptide Aβ(1–28)

Free radicals in Alzheimer's disease: From pathophysiology to clinical trial results

Reaction rates and mechanism of the ascorbic acid oxidation by molecular oxygen facilitated by Cu(II)-containing amyloid-beta complexes and aggregates.

Oxidative Stress Induces DNA Demethylation and Histone Acetylation in SH-SY5Y Cells: Potential Epigenetic Mechanisms in Gene Transcription in Aβ Production

Oxidative stress and the pathogenesis of Alzheimer's disease.

Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease

Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Misfolded protein oligomers induce an increase of intracellular Ca2+ causing an escalation of reactive oxidative species

Truncated and Modified Aβ Species in Alzheimer's Disease

Aβ1-16 Can Aggregate and Induce the Production of Reactive Oxygen Species, Nitric Oxide, and Inflammatory Cytokines.

The Role of Reactive Oxygen Species in Alzheimer's Disease: from Mechanism to Biomaterials Therapy.

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

Cellular defense against oxidized low density lipoproteins and fibrillar amyloid beta in murine cells of monocyte origin with possible susceptibility to the oxidative stress induction

The Role of Reactive Oxygen Species in Alzheimer's Disease:from Mechanism to Biomaterials Therapy

Real-Time Detection and Visualization of Amyloid-β Aggregates Induced by Hydrogen Peroxide in Cell and Mouse Models of Alzheimer's Disease